Therapy of Cancer Metastasis by Systemic Activation of Macrophages
Advances in Pharmacology, ISSN: 1054-3589, Vol: 30, Issue: C, Page: 271-326
1994
- 40Citations
- 11Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations40
- Citation Indexes40
- 40
- CrossRef27
- Captures11
- Readers11
- 11
Article Description
During the past decade, the role of macrophages in host defense against cancer has attracted considerable attention. This interest stems in part from data showing that monocytes-macrophages can become activated to lyse tumor cells under both in vitro and in vivo conditions. This chapter discusses the molecular events that regulate the process of macrophage activation to recognize and destroy tumorigenic cells, the methods to achieve reproducible systemic activation of macrophages, and findings from preclinical and clinical studies of macrophage activation in cancer treatment protocols. These data suggest that the integration of systemic macrophage activation into multimodality treatment protocols can improve the survival of patients with metastatic cancer. The heterogeneous nature of neoplasms and the developed treatment resistance of variant cells imply that the successful therapy of disseminated cancer must include a modality that can overcome these obstacles. The systemic activation of macrophages with liposomes containing biological agents can meet these challenges. Tumoricidal macrophages selectively bind to and destroy malignant cells in vitro and in vivo while leaving nonneoplastic cells unharmed. Moreover, macrophage-mediated lysis of tumor cells is not associated with the development of significant tumor cell resistance.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1054358908601775; http://dx.doi.org/10.1016/s1054-3589(08)60177-5; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0028706342&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/7833294; http://linkinghub.elsevier.com/retrieve/pii/S1054358908601775; https://linkinghub.elsevier.com/retrieve/pii/S1054358908601775; http://dx.doi.org/10.1016/s1054-3589%2808%2960177-5; https://dx.doi.org/10.1016/s1054-3589%2808%2960177-5
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know